A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C)-MedSci.cn

A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C)

Waller, C; Vutikullird, A; Lawrence, T; Shaw, A; Liu, MS; Baczkowski, M; Sharma, R; Barve, A; Pennella, E

EUROPEAN JOURNAL OF CANCER, 2017; 72 ( ): S40

科室
- - 订阅+
  - 更多科室
工具
服务